Перейти к основному содержанию
AkademIndex

Продукты

Для разработчиков

AkademBaseОткрытый API экосистемы
← Назад к работе

Работы, на которые ссылается эта работа

Работ: 194

Работа: An odyssey of monoclonal gammopathies: focusing on precursors and the progression from MGUS and SMM to multiple Myeloma, with a brief overview of novel therapeutic strategies

  1. The Benefits and Safety of Monoclonal Antibodies: Implications for Cancer Immunotherapy

    Shuguang Zhang, Wen‐Ying Chen, Jihong Zhou +5

    Обзорная статья2025Цитирований: 7
    ABI

  2. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

    Nikhil C. Munshi, Larry D. Anderson, Nina Shah +25

    Статья2021Цитирований: 5
    ABI

  3. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management

    S. Vincent Rajkumar

    Статья2022Цитирований: 4
    ABI

  4. The Emerging Role of Super-enhancers as Therapeutic Targets in The Digestive System Tumors

    Xiangping Li, Jian Qu, Xin-Qi Teng +4

    Обзорная статья2023Цитирований: 3
    ABI

  5. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

    Jesús G. Berdeja, Deepu Madduri, Saad Z. Usmani +33

    Статья2021Цитирований: 3
    ABI

  6. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms

    Rita Alaggio, Catalina Amador, Ioannis Anagnostopoulos +80

    Обзорная статья2022Цитирований: 3
    ABI

  7. Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma

    Larysa Sanchez, Yucai Wang, David S. Siegel +1

    Обзорная статья2016Цитирований: 2
    ABI

  8. Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression

    Mark Bustoros, Romanos Sklavenitis‐Pistofidis, Jihye Park +33

    Статья2020Цитирований: 2
    ABI

  9. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project

    Mattia D’Agostino, David A. Cairns, Juan José Lahuerta +28

    Статья2022Цитирований: 2
    ABI

  10. Multiple myeloma

    Florent Malard, Paola Neri, Nizar J. Bahlis +5

    Обзорная статья2024Цитирований: 2
    ABI

  11. Circulating immune cells and risk of osteosarcoma: a Mendelian randomization analysis

    Li Lan, Yeqi Sun, Jia Luo +1

    Статья2024Цитирований: 2
    ABI

  12. Plasma cell neoplasms and related entities—evolution in diagnosis and classification

    Falko Fend, Ahmet Doǧan, James R. Cook

    Обзорная статья2022Цитирований: 2
    ABI

  13. Monoclonal Gammopathy of Undetermined Significance

    Wilson I. Gonsalves, S. Vincent Rajkumar

    Обзорная статья2022Цитирований: 2
    ABI

  14. Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma

    Robert A. Kyle, Ellen D. Remstein, Terry M. Therneau +9

    Статья2007Цитирований: 2
    ABI

  15. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

    Joaquín Martínez‐López, Juan José Lahuerta, François Pépin +21

    Статья2014Цитирований: 2
    ABI

  16. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance

    S. Vincent Rajkumar, Robert A. Kyle, Terry M. Therneau +7

    Статья2005Цитирований: 2
    ABI

  17. High applicability of ASO-RQPCR for detection of minimal residual disease in multiple myeloma by entirely patient-specific primers/probes

    Yinlei Bai, Kwan Yeung Wong, Tsz Kin Fung +1

    Другое2016Цитирований: 2
    ABI

  18. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing

    Leo Rasche, Shweta S. Chavan, Owen Stephens +19

    Статья2017Цитирований: 2
    ABI

  19. Lymphocyte Subsets and Inflammatory Cytokines of Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma

    Alessandro Allegra, Vanessa Innao, Andrea Gaetano Allegra +5

    Обзорная статья2019Цитирований: 2
    ABI

  20. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

    Elı́as Campo, Elaine S. Jaffe, James R. Cook +70

    Статья2022Цитирований: 2
    ABI

  21. High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma

    Luca Bertamini, Stefania Oliva, Delia Rota‐Scalabrini +26

    Статья2022Цитирований: 2
    ABI

  22. Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma

    Juan‐José Garcés, María‐Teresa Cedena, Noemí Puig +25

    Статья2022Цитирований: 2
    ABI

  23. More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia–Like Multiple Myeloma

    Tomáš Jelı́nek, Renata Bezděková, David Žihala +27

    Статья2022Цитирований: 2
    ABI

  24. Chromosomal defects in multiple myeloma

    Sarah E. Clarke, Kathryn A. Fuller, Wendy N. Erber

    Обзорная статья2024Цитирований: 2
    ABI

  25. Genomic Classification and Individualized Prognosis in Multiple Myeloma

    Francesco Maura, Arjun Raj Rajanna, Bachisio Ziccheddu +34

    Статья2024Цитирований: 2
    ABI